Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 106 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
1051 11.0 months Newly diagnosed GBM 5 Chemotherapy
Radiation
University of Tubingen Medical School Germany 1/2001
Treatment Details: Patients: Twenty-one patients with newly diagnosed glioblastoma were enrolled in this Phase II study. Treatment: The treatment consisted of preirradiation chemotherapy gemcitabine (ge
 
1052 11.0 months Newly diagnosed GBM 3 Chemotherapy
Radiation
University Hospital, Kragujevac Yugoslavia 1/2001
Treatment Details: Patients: This Phase II study involved 79 patients comprised of 61 glioblastoma multiforme patients and 18 patients with anaplastic astrocytoma. Treatment: Treatment consisted of radiatio
 
1053 11.0 months Newly diagnosed GBM 5 Chemotherapy
Radiation
Johns Hopkins United States 4/2003
Treatment Details: Patients: In the experimental arm of this Phase III study, there were 109 Patients with newly diagnosed supratentorial glioblastoma multiforme (one patient was classified as having a gliosar
 
1054 11.0 months Newly diagnosed GBM 4 Chemotherapy
Radiation
Dartmouth-Hitchcock Medical Center United States 6/2003
Treatment Details: Patients: This Phase II study involved 108 patients with newly diagnosed glioblastoma multiforme. (Only 104 were “analyzable.”) Patients were divided into two groups – 55 patients in Group
 
1055 11.0 months NSCLC 4 Chemotherapy
Istituto Nazionale per lo Studio e la Cura dei Tumori Italy 2/2003
Treatment Details: Patients: This Phase II study involved 86 patients with stage IV non-small-cell lung cancer. None of the patients had prior chemotherapy. Treatment: The treatment consisted of two drugs
 
1056 11.0 months Advanced NSCLC 4 Chemotherapy
Hospital Central de Asturias Spain 8/2002
Treatment Details: Patients: This Phase I/II study involved 65 patients with advanced (stage IIIA, IIIB, or IV) non-small cell lung cancer. None of the patients had received prior chemotherapy or radiotherapy
 
1057 11.0 months Hormone-refractory prostate cancer 5 Biologic therapy
Clinica Universitaria de Navarra Spain 11/2001
Treatment Details: Patients: This multicenter Phase II trial involved 50 patients with hormone refractory prostate cancer. The median age was 67.5. The median PSA was 306.81 (ranged from .2 – 4200). Metasta
 
1058 11.0 months Hormone-refractory prostate cancer 4 Radiation
Academic Hospital Netherlands 11/2003
Treatment Details: Patients: This Phase III study involved a total of 203 patients. Patients were divided into two groups: Group 1 with 101 patients and Group 2 with 102 patients. Median PSA for patients in
 
1059 11.0 months Platinum Resistent NSCLC 4 Chemotherapy
San Filippo Neri Hospital Italy 5/2005
Treatment Details: Patients: This Phase II study involved 58 patients (44 men, 14 women) with platinum-refractory non-small-cell lung cancer. The median age was 60 years. Forty patients had two or more metas
 
1060 11.0 months metastatic ovarian cancer 4 Chemotherapy
Laikon General Hospital Greece 8/2005
Treatment Details: Patients: This Phase II study involved 31 patients with metastatic ovarian cancer. The median age was 60 years. Nineteen women had stage IIIc ovarian cancer, and twelve had stage IV. All
 
Page 106 of 187  | Previous Page  | Next Page